肝素对开放手术修复破裂腹主动脉瘤术后死亡率的影响
基于血管质量倡议数据库2003至2020年的回顾性队列研究,比较开放修复破裂腹主动脉瘤术中接受与未接受肝素的患者。倾向评分匹配后519对患者显示,肝素组30天死亡率更低(风险比0.74),10年生存率更高(风险比0.62),但肝素使用可能反映患者本身更健康。
要点
- 倾向评分匹配后,肝素组30天死亡率低于未肝素组(风险比0.74,95%CI 0.66-0.84)。
- 肝素组10年生存率更高,死亡风险约为未肝素组的0.62倍(95%CI 0.53-0.72,P<0.0001)。
- 肝素组术中估计失血量少910 mL,输注浓缩红细胞少17单位。
核心结论
- 开放修复破裂腹主动脉瘤时接受全身肝素的患者,30天内和10年均有显著短期和长期生存获益。
- 肝素可能带来死亡获益,也可能是术中患者更健康、濒死状态更轻的替代标志。
研究设计与样本
- 回顾性队列研究,比较2003至2020年血管质量倡议数据库中接受与未接受肝素的行开放修复破裂腹主动脉瘤患者。
- 共纳入2410例患者,其中1853例接受术中肝素,557例未接受。
- 基于25个变量进行倾向评分匹配,得到519对肝素与无肝素比较。
- 主要结局为30天死亡率和10年死亡率;次要结局包括估计失血量、输注浓缩红细胞单位数、术后早期输血和术后并发症。
- 二分类结局使用相对风险比较,连续变量分别使用配对t检验和Wilcoxon秩和检验;生存分析使用Kaplan-Meier曲线和Cox比例风险模型。
主要发现
- 肝素组30天死亡率低于无肝素组(风险比0.74;95%CI 0.66-0.84)。
- 肝素组院内死亡率低于无肝素组(风险比0.68;95%CI 0.60-0.77)。
- 肝素组估计失血量少910 mL(95%CI 230 mL至1590 mL)。
- 肝素组术中及术后输注浓缩红细胞平均单位数少17单位(95%CI 8-42)。
- 接受肝素的患者10年生存率更高,生存率约比未接受肝素者高40%(风险比0.62;95%CI 0.53-0.72;P<0.0001)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 肝素使用可能带来死亡获益,也可能是术中患者更健康、濒死状态更轻的替代标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic administration of heparin is widely used in patients undergoing open elective abdominal aortic aneurysm (AAA) repair. However, no clear consensus exists in the use of intraoperative heparin during open ruptured AAA (rAAA) repair. In this study, we assessed the safety of intravenous heparin administration in patients undergoing open rAAA repair. METHODS: A retrospective cohort study comparing patients who received and did not receive heparin during open rAAA repair in the Vascular Quality Initiative database between 2003 and 2020 was conducted. The primary outcomes were 30-day and 10-year mortality. The secondary outcomes included estimated blood loss, number of packed red blood cells transfused, early postoperative transfusions, and postsurgical complications. Propensity score matching was used to adjust for potentially confounding variables. The outcomes were compared between the 2 groups using relative risk for binary outcomes and paired t-test and the Wilcoxon rank-sum test for normally and non-normally distributed continuous variables, respectively. Survival was examined using Kaplan-Meier curves and compared using a Cox proportional hazards model. RESULTS: A total of 2,410 patients who underwent open rAAA repair between 2003 and 2020 were studied. Of the 2,410 patients, 1,853 patients received intraoperative heparin and 557 did not. Propensity score matching on 25 variables yielded 519 pairs for the heparin to no heparin comparison. Thirty-day mortality was lower in the heparin group (risk ratio: 0.74; 95% confidence interval [CI]: 0.66-0.84) and in-hospital was also lower in the heparin group (risk ratio: 0.68; 95% CI: 0.60-0.77). Furthermore, estimated blood loss was 910 mL (95% CI: 230 mL to 1,590 mL) lower in the heparin group and the mean number of packed red blood cells transfused intraoperatively and postoperatively were 17 units lower in the heparin group (95% CI: 8-42). Ten-year survival was higher for patients who received heparin, and their rate of survival was approximately 40% higher than those who did not receive heparin (hazard ratio: 0.62; 95% CI, 0.53-0.72; P < 0.0001). CONCLUSIONS: In patients who received systemic heparin administration at the time of open rAAA repair, there were significant short-term and long-term survival benefits within 30 days and at 10 years. Heparin administration may have afforded a mortality benefit or been a surrogate for healthier and less moribund patients at the time of the procedure.
引用
- Cuen-Ojeda C, Li B, Tam DY, et al. The Impact of Heparin on Mortality Following Open Ruptured Abdominal Aortic Aneurysm Repair. Ann Vasc Surg. 2023. PMID: 37019358. doi:10.1016/j.avsg.2023.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。